See more : Taier Heavy Industry Co., Ltd. (002347.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of BioLineRx Ltd. (BLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLineRx Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- AMREP Corporation (AXR) Income Statement Analysis – Financial Results
- Franklin Financial Services Corporation (FRAF) Income Statement Analysis – Financial Results
- Ji-Haw Industrial Co.,Ltd. (3011.TW) Income Statement Analysis – Financial Results
- Markray Corp. (RVBR) Income Statement Analysis – Financial Results
- Christian Berner Tech Trade AB (publ) (CBTT-B.ST) Income Statement Analysis – Financial Results
BioLineRx Ltd. (BLRX)
About BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.16M | 113.16M | 63.91M | 31.89M |
Cost of Revenue | 3.69M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 440.89K | 0.00 | 0.00 | 0.00 | 22.62M | 7.21M |
Gross Profit | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | -451.00K | -480.68K | -481.89K | -440.89K | 0.00 | 113.16M | 113.16M | 41.29M | 24.69M |
Gross Profit Ratio | 23.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 64.60% | 77.40% |
Research & Development | 12.52M | 17.63M | 19.47M | 18.17M | 23.44M | 19.81M | 19.51M | 11.18M | 11.49M | 10.90M | 12.65M | 17.21M | 11.20M | 15.49M |
General & Administrative | 16.64M | 5.07M | 4.27M | 3.84M | 3.74M | 4.41M | 4.04M | 3.95M | 3.65M | 3.49M | 3.68M | 3.71M | 3.34M | 4.14M |
Selling & Marketing | 14.59M | 6.46M | 1.00M | 840.00K | 857.00K | 1.36M | 1.69M | 1.35M | 1.00M | 1.46M | 1.18M | 863.77K | 869.15K | 1.30M |
SG&A | 31.23M | 11.53M | 5.27M | 4.68M | 4.60M | 5.77M | 5.73M | 5.31M | 4.65M | 4.95M | 4.86M | 4.57M | 4.21M | 5.44M |
Other Expenses | 7.05M | 5.67M | 42.00K | 70.00K | 78.00K | 27.00K | -260.00K | 7.00K | 153.00K | 2.81M | -280.83K | -322.27K | 0.00 | 50.17K |
Operating Expenses | 50.80M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 20.98M |
Cost & Expenses | 54.49M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 28.19M |
Interest Income | 2.01M | 694.00K | 559.00K | 236.00K | 777.00K | 719.00K | 1.17M | 480.00K | 457.00K | 3.28M | 746.59K | 2.36M | 3.34M | 861.33K |
Interest Expense | 2.17M | 2.16M | 984.00K | 1.47M | 1.83M | 21.00K | 21.00K | 14.00K | 15.00K | 411.67K | 20.67K | 25.96K | 1.12M | 16.63K |
Depreciation & Amortization | 1.38M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 441.00K | 246.54K | 329.36K | 407.93K | 410.67K | 511.28K |
EBITDA | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | -25.15M | -23.83M | -15.34M | -13.94M | -10.79M | -16.70M | -19.38M | -13.59M | 4.21M |
EBITDA Ratio | -1,188.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14.88% | -18.90% | -23.47% | 20.90% |
Operating Income | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | -25.61M | -25.24M | -16.51M | -16.20M | -15.85M | -17.63M | -21.83M | -15.41M | 3.70M |
Operating Income Ratio | -1,035.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.58% | -19.29% | -24.11% | 11.61% |
Total Other Income/Expenses | -10.92M | 4.21M | -2.28M | -7.09M | 2.67M | 2.64M | 888.00K | 672.00K | 1.80M | 6.18M | -13.16K | 1.37M | 1.39M | -1.61M |
Income Before Tax | -60.61M | -24.95M | -27.05M | -30.02M | -25.45M | -22.96M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | 61.52M | 2.10M |
Income Before Tax Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | 96.26% | 6.57% |
Income Tax Expense | 1.00K | -6.08M | 1.09M | 911.00K | 1.36M | -4.46M | -888.00K | -672.00K | -1.80M | -5.68M | 15.79K | -1.42M | -2.22M | 1.61M |
Net Income | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M | -18.51M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | -13.19M | 2.10M |
Net Income Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | -20.63% | 6.57% |
EPS | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
EPS Diluted | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
Weighted Avg Shares Out | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 823.41K |
Weighted Avg Shares Out (Dil) | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 830.31K |
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
Source: https://incomestatements.info
Category: Stock Reports